Peerview Neuroscience & Psychiatry Cme/cne/cpe Audio Podcast

Go online to PeerView.com/QVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. After almost two decades without a new AD treatment, recent advances in disease-modifying therapies—including the accelerated FDA approval of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have introduced the possibility of slowed disease progression and improved patient outcomes. Furthermore, significant advances have been made in identifying and testing biomarkers for AD that may aid in early diagnosis, proper treatment selection, and assessment of therapeutic response. The latter is increasingly important given the need to monitor for amyloid-related imaging abnormalities (ARIA) in patients being prescribed ATTs for mild cognitive impairment due to AD or mild AD dementia. With the rapid deve